FBRX
Forte Biosciences, Inc.Company with tickers: FBRX
CIK
1419041
CUSIP
34962G208
Shares Outstanding
20,478,817
13F Activity (30d)
23 filings
23 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Paul A. Wagner, Ph.D. | Class III director | Appointed | 2026-06-02 |
| Scott Brun, M.D. | Class III director | Appointed | 2026-06-02 |
| Steven Kornfeld | Class III director | Appointed | 2026-06-02 |